Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Truist Financial Corporation Common Stock (TFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Truist Financial Corporation Common Stock — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.59 (market cap $12.58B), while Truist Financial Corporation Common Stock trades at $46.18 (market cap $56.41B). The key difference: Truist Financial Corporation Common Stock is far larger — about 4.5× Halozyme Therapeutics Inc. Common Stock's market cap, and Truist Financial Corporation Common Stock pays a 4.5% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Truist Financial Corporation Common Stock for 1 Days on average.
| HALO | TFC | |
|---|---|---|
Market Cap | $12.58B | $56.41B |
Volume | 2,179,278 | 9,045,741 |
Sector | Health | Financials |
52-Week High | $115.22 | $55.81 |
52-Week Low | $61.63 | $41.09 |
Typical Hold Time | 1 Days | 1 Days |
Enterprise Value | $14.49B | $122.69B |
Dividend Yield | — | 4.5% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Truist Financial Corporation Common Stock
Truist Financial provides consumer and commercial banking, wealth management, insurance, and investment services in the United States.
Read more on TFC →
